KURA ONCOLOGY, INC. Increase (Decrease) in Other Accrued Liabilities
KURA ONCOLOGY, INC. (KURA) reported Increase (Decrease) in Other Accrued Liabilities of -$4.00 thousand for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2012-05-15
- KURA ONCOLOGY, INC. increase (decrease) in other accrued liabilities for the quarter ending 2012-03-31 was -$4.00K.
- KURA ONCOLOGY, INC. increase (decrease) in other accrued liabilities for the quarter ending 2011-03-31 was -$1.01K.
- KURA ONCOLOGY, INC. increase (decrease) in other accrued liabilities for fiscal 2011 was $0.00.
- KURA ONCOLOGY, INC. increase (decrease) in other accrued liabilities for fiscal 2010 was $0.00.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 12 month | Increase (Decrease) in Other Accrued Liabilities 49 month | Increase (Decrease) in Other Accrued Liabilities 52 month |
|---|---|---|---|---|
| 2012-03-31 | -$4.00K 10-Q · filed 2012-05-15 | $1.50K 10-Q · filed 2012-05-15 | ||
| 2011-12-31 | $0.00 10-K · filed 2012-03-30 | $5.50K 10-K · filed 2012-03-30 | ||
| 2011-03-31 | -$1.01K 10-Q · filed 2012-05-15 | |||
| 2010-12-31 | $0.00 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |